Tutti gli studi
ReclutamentoFASE3INTERVENTISTICO

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

This research study, called YOSEMITE, is looking into a new medicine called zodasiran. It's for teenagers and adults, aged 12 and over, who have a rare and severe inherited condition called homozygous familial hypercholesterolemia (HoFH). HoFH causes extremely high cholesterol levels from birth, which can lead to serious heart problems at a young age. The study aims to find out if zodasiran injections are safe and effective at lowering these high cholesterol levels. Some participants will receive zodasiran, while others will receive a dummy medicine (placebo) first, before everyone eventually gets the active drug. Your participation could help improve treatments for HoFH in the future.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE3
Sponsor
Arrowhead Pharmaceuticals
Obiettivo di iscrizione
60
Inizio
17 giu 2025
Completamento stimato
20 Aug 2027

Di cosa tratta questo studio?

Imagine your body struggling to clear out bad cholesterol, leading to dangerously high levels from a very young age. This is what happens to people with Homozygous Familial Hypercholesterolemia (HoFH), a rare and serious inherited condition. These extremely high cholesterol levels can cause serious health problems, including heart disease, much earlier in life than usual.

This study, named YOSEMITE, is testing a new medicine called zodasiran. Researchers want to see if zodasiran can safely and effectively lower the very high cholesterol levels in people aged 12 and over with HoFH. By taking part, you could help doctors understand more about how to manage this condition and potentially improve future treatments.

The study is 'double-blind', meaning neither you nor your doctor will know if you are receiving zodasiran or a dummy medicine (placebo) at first. This helps ensure the results are accurate. After this initial period, everyone will have the chance to receive the actual zodasiran medicine in a longer, open-label part of the study.

Punti chiave

  • This study is testing a new medicine for severe inherited high cholesterol (HoFH).
  • It's for people aged 12 and above.
  • Participants will receive either zodasiran or a dummy medicine first.
  • Everyone can eventually receive the active medicine.
  • The goal is to see if zodasiran can safely lower cholesterol levels.
  • Your participation could help advance HoFH treatment.

Chi può essere idoneo?

To join this study, you would need to be at least 12 years old and weigh at least 35 kg (about 5 stone 7 pounds). If you can become pregnant, you shouldn't be pregnant or breastfeeding, and should not plan to become pregnant during the study.

You would need to have a confirmed diagnosis of HoFH, either through a genetic test or based on certain cholesterol levels and other signs like fatty deposits on your skin or tendons from a young age. Your 'bad' cholesterol (LDL-C) levels would also need to be above a certain amount, even if you're already taking cholesterol-lowering medicines.

There are also some health conditions or medicines that would prevent you from joining. For example, if you've recently used certain other trial medicines or have severe kidney problems, you might not be able to take part. The study also requires you to be stable on your current cholesterol-lowering medicines.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you 12 years old or older?
  2. Do you have a diagnosis of HoFH?
  3. Are you currently on cholesterol-lowering medicines?
  4. If female, are you not pregnant or breastfeeding, and not planning to become pregnant during the study?
  5. Are your cholesterol levels still high despite existing treatment?
  6. Do you meet the weight requirement of at least 35 kg?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to join, you'll first be randomly assigned to receive either the study medicine, zodasiran, or a dummy medicine (placebo) through injections under your skin. Neither you nor your study doctor will know which you are receiving at this stage. This initial 'double-blind' period will last for several months.

Throughout the study, you'll have regular visits to the clinic for health checks, blood tests, and to make sure the treatment is working and you're not experiencing any problems. After the initial period, you'll have the option to continue in a longer part of the study where everyone will receive the active zodasiran medicine. We don't have the exact number of visits or the total length of the study available right now, but these details would be explained fully by the study team.

Rischi e benefici potenziali

Taking part in a study like this can have potential benefits, such as receiving a new treatment that might help lower your cholesterol levels. You'll also receive close medical attention and contribute valuable information that could help others with HoFH in the future. However, there are also potential risks, including side effects from the study medicine or discomfort from injections and blood tests. Remember, you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (43)

  • Research Site 7
    Codice postale verificato
    Park Ridge, United States· Reclutamento
  • Research Site 2
    Codice postale verificato
    New York, Stati Uniti· Reclutamento
  • Research Site 1
    Codice postale verificato
    Cincinnati, Stati Uniti· Reclutamento
  • Research Site 14
    Codice postale verificato
    Pittsburgh, United States· Reclutamento
  • Research Site 13
    Codice postale verificato
    Camperdown, Australia· Reclutamento
  • Research Site 9
    Solo città
    Saint Leonards, Australia· Reclutamento
  • Research Site 21
    Codice postale verificato
    Heidelberg, Australia· Reclutamento
  • Research Site 3
    Codice postale verificato
    Nedlands, Australia· Reclutamento
  • Research Site 40
    Codice postale verificato
    Innsbruck, Austria· Reclutamento
  • Research Site 39
    Codice postale verificato
    Linz, Austria· Reclutamento
  • Research Site 42
    Codice postale verificato
    Vienna, Austria· Reclutamento
  • Research Site 37
    Codice postale verificato
    Vienna, Austria· Reclutamento

Domande comuni

What is HoFH?

HoFH (Homozygous Familial Hypercholesterolemia) is a very rare inherited condition that causes extremely high cholesterol levels from birth, leading to a high risk of heart disease at a young age.

What is zodasiran?

Zodasiran is an investigational medicine being tested in this study to see if it can help lower very high cholesterol levels in people with HoFH.

What is a 'placebo'?

A placebo is a dummy treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers accurately see if the real medicine is effective.

Sapró se sto ricevendo la medicina vera?

For the first part of the study, neither you nor your doctor will know if you're getting zodasiran or the placebo. Later, everyone will have the option to receive the active zodasiran.

How is the medicine given?

The study medicine, zodasiran, is given as an injection under the skin.

Come saperne di più

Medical Monitor

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Phase 3 Study of Zodasiran in Adolescent and Adult Subject…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.